Selective covalent capture of DNA sequences
By forming covalent crosslinking in double-stranded nucleic acid molecules, the problem of signal degradation and insufficient selectivity in covalent chemistry when capturing nucleic acid sequences in biological analysis is solved, and efficient and stable detection of specific nucleic acid sequences is achieved. In particular, It is excellent in selective capture of mutant KRAS gene sequences.
Patent Information
- Application Number
- CN202080066678.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-09
- Filing Date
- 2020-08-10
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-08-10
AI Technical Summary
In the prior art, covalent chemistry lacks practical and predictable covalent capture reactions when used in biological analysis to detect nucleic acid sequences, resulting in signal degradation and insufficient selectivity, especially when detecting specific nucleic acid target sequences, it is difficult to achieve high efficiency. and stability.
By incubating hybrid double-stranded nucleic acid molecules, including the 2'-deoxyguanosine (dG) target strand to be crosslinked and a base-free (Ap) residue, the Ap residues of the probe strand are located at the target dG The 3' position of the residue and covalent crosslinking is formed in the presence of NaCNBH3, and a stable covalent crosslinking probe-target complex is generated using a reduction amination reaction, improving the selectivity and stability of the detection.
It realizes efficient selective capture and detection of specific nucleic acid sequences, enhances signal stability, and can simultaneously detect the presence and absence of target sequences, significantly improving the covalent capture yield and selectivity of mutant KRAS gene sequences. .
Smart Images

Figure CN114599799B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is a PCT international application claiming the benefit of U.S. Provisional Application Serial No. 62 / 884,867, filed on August 9, 2019, which is incorporated herein by reference in its entirety.
[0003] References to sequence listings submitted electronically
[0004] The contents of the sequence listing in the electronically submitted ASCII text file (name UMC_52553_19893_Seq_List.ST25.txt; size: 5640 bytes; creation date: August 10, 2020) submitted with the application are incorporated herein by reference in their entirety.
[0005] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0006] This invention was made with government support under HG009338 awarded by the National Institutes of Health, ES021007 awarded by the National Institutes of Health, and GM114204 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art
[0007] Many bioanalytical applications employ covalent chemistry to generate robust signals for detecting bioactive small molecules (Secor, 2004; Kumar, 2013), proteins (Chen, 2013; Sletten, 2009; Takaoka, 2013), protein-protein complexes (Krishnamurthy, 2011; Pham, 2013; Sutherland, 2008), protein-nucleic acid complexes (Hoffman, 2015; Simon, 2016; Engreitz, 2014), RNA-RNA interactions (Simon, 2016; Engreitz, 2014), chromatin structure (Yu, 2018), and proteins with specific functional properties (Cravatt, 2008; Willems, 2014). Detection of specific nucleic acid sequences is important in molecular biology and medicine (Katsanis, 2013), but covalent approaches are less common in this field, in part due to the lack of practical, predictable (programmable) reactions for covalent attachment of probes to target sequences. Nucleic acid sequence detection almost universally relies on Watson-Crick pairing of nucleic acid probe strands to target sequences in a sample (Demidov, 2004). Covalent cross-linking reactions can be used to anchor probe strands to their target sequences, thereby generating probe-target complexes that are not affected by denaturation (melting) that would result in signal degradation in typical hybridization-based assays ( Fig.14 )(Vieregg, 2013; Simon, 2016; Costes, 1993). In addition, sequence-specific covalent cross-linking reactions can add a layer of selectivity for specific target sequences (Peng, 2008; Hattori, 2009; Nishimoto, 2013; Stevens, 2009; Fujimoto, 2013). For example, selective cross-links formed by dichloromethyldiethylamine at CC mismatches in the probe-target complex have been shown to be used to selectively detect disease-associated T→C mutations in the BRAF kinase gene sequence (Shi, 2018). In a separate study, a reactive probe containing an abasic (Ap) site was used to selectively detect the T→A polymorphism in the BRAF gene (Imani-Nejad, 2017). In this case, the covalent cross-linking of the probe strand to the target strand involves the reaction of the Ap aldehyde group in the probe with the exocyclic amino group of the adenine mutation in the target strand (Price, 2014; Catalano, 2016). Summary of the invention
[0008] Provided herein is a method for producing a covalently cross-linked nucleic acid chain, the method comprising incubating a hybridized double-stranded nucleic acid molecule comprising: (i) a target chain comprising a 2'-deoxyguanosine (dG) (target dG) to be cross-linked; and (ii) an at least partially complementary probe chain comprising an abasic (Ap) residue, wherein in the hybridized nucleic acid molecule, the Ap residue of the probe chain is located at a position 3' of a nucleotide residue in the probe chain that is directly opposite to the target dG in the target chain, and wherein incubation occurs under conditions that allow covalent cross-links to form between the Ap residue of the probe chain and the target dG; thereby producing a covalently cross-linked nucleic acid chain. In certain embodiments, incubation occurs in the presence of NaCNBH3. In certain embodiments, incubation occurs at a pH value of less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0, for example, at or at about pH 5.1, pH 5.2, or pH 5.3.
[0009] Provided herein is a method for detecting the presence or absence of a dG residue (target dG) at a specific position in a nucleic acid target strand, the method comprising incubating a hybridized double-stranded nucleic acid molecule comprising: (i) a target strand; and (ii) a probe strand comprising at least a portion of a complementary abasic (Ap) residue, wherein the Ap residue of the probe strand is located immediately adjacent to the 3' position of a nucleotide residue in the probe strand that is directly opposite to a specific position in the target strand where the presence or absence of the target dG residue is to be detected, wherein the incubation occurs under conditions that allow the formation of a covalent crosslink between the Ap residue in the probe strand and the target dG residue (if present) in the target strand; and detecting whether the target strand and the probe strand are crosslinked, thereby detecting the presence or absence of the target dG residue at a specific position in the target strand. In certain embodiments, the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules. In certain embodiments, the target strand comprises genomic or mitochondrial DNA. In certain embodiments, the covalent crosslinking of the probe strand and the target strand is detected by gel electrophoresis, thermal stability monitoring, fluorescence (i.e., FRET), electrochemistry, surface plasmon resonance, or a nanopore-based sensor, and optionally wherein the covalent crosslinking of the probe strand and the target strand is detected by a nanopore-based sensor. In certain embodiments, the detection is quantitative. In certain embodiments, incubation occurs in the presence of NaCNBH3. In certain embodiments, incubation is less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0, for example, at or at about pH 5.1, pH 5.2, or pH 5.3.
[0010] Provided herein are methods for detecting a mutation in a wild-type sequence, the methods comprising detecting the presence or absence of a target dG residue at a specific position in a target strand according to any of the methods disclosed herein.
[0011] Provided herein is a method for detecting the presence of a dG residue in a nucleic acid strand, the method comprising incubating a hybridized double-stranded nucleic acid molecule comprising: (i) a target strand comprising a dG residue to be detected (target dG); and (ii) an at least partially complementary probe strand comprising an abasic (Ap) residue, wherein in the hybridized molecule, the Ap residue of the probe strand is located at a position 3' of a nucleotide residue in the probe strand that is directly opposite to the target dG residue in the target strand, and wherein the incubation occurs under conditions that allow covalent crosslinks to form between the Ap residue in the probe strand and the target dG residue in the target strand; and detecting the covalent crosslinks between the AP residue in the probe strand and the target dG in the probe strand, thereby detecting the presence of the target dG residue in the target strand. In certain embodiments, the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules. In certain embodiments, the target strand is genomic or mitochondrial DNA. In certain embodiments, the covalent crosslinking of the probe strand and the target strand is detected by gel electrophoresis, thermal stability monitoring, fluorescence (i.e., FRET), electrochemistry, surface plasmon resonance, or a nanopore-based sensor, and optionally wherein the covalent crosslinking of the probe strand and the target strand is detected by a nanopore-based sensor. In certain embodiments, the detection is quantitative. In certain embodiments, incubation occurs in the presence of NaCNBH3. In certain embodiments, incubation is less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0, for example, at or at about pH 5.1, pH 5.2, or pH 5.3.
[0012] Provided herein are covalently cross-linked hybridized double-stranded nucleic acid molecules, comprising a probe strand containing an abasic (Ap) residue and a target strand containing a 2'-deoxyadenosine (dG) residue, wherein the Ap residue is located at the 3' position of a nucleotide residue in the probe strand that is directly opposite to the dG residue in the target strand, and wherein the Ap residue is covalently cross-linked to the dG residue in the target strand, and the dG residue in the target strand is directly opposite to the nucleotide residue in the probe strand that is immediately adjacent to the 3' of the AP residue. In certain embodiments, the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules. In certain embodiments, the target strand comprises genomic or mitochondrial DNA. And, in certain embodiments, the nucleic acid molecules are isolated. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1A,BFigure 1 shows the selective covalent capture of the sequence corresponding to KRAS nc35C>G by probes 1 and 12. The probe-target duplex was incubated for 24 hours at 37°C in sodium acetate (750 mM, pH 5.2) buffer containing NaCNBH3 (200 mM). Formamide loading buffer was added, and the DNA in the sample was resolved by electrophoresis on a denaturing 20% polyacrylamide gel. After separation, the gel was 32 P-labeled oligonucleotides were visualized by phosphorphase analysis. A: Covalent capture of mutant and wild-type KRAS sequences by probe 1. Lane 1: 5'- 32 P-labeled probe 1 containing AP; Lane 2: Probe 1 treated with piperidine to induce cleavage at the Ap site; Lane 3: Crosslink formation in the probe-mutant complex; Lane 4: Crosslink formation in the probe-wild-type complex. B: Covalent capture of mutant and wild-type KRAS sequences by probe 12. Lane 1: 5'- 32 P-labeled AP-containing probe 12; Lane 2: probe 12 treated with piperidine to induce cleavage at the Ap site; Lane 3: cross-link formation in the probe-mutant complex; Lane 4: cross-link formation in the probe-wild-type complex. The values shown are the average and standard deviation calculated from three or more measurements.
[0014] Figure 2 . Figure 2 The yield and selectivity of covalent capture (cross-linking) of mutant KRAS and WT KRAS gene sequences by reactive AP-containing probes (X=Ap in the sequence shown) are shown. The cross-linking reaction and gel electrophoresis analysis were performed as described in Figure 1. The sequence of probe 1 was designed to generate a completely base-paired probe-target complex. Probes 2-5 formally introduced mismatches at different positions in the probe-target complex (underlined in the sequence shown). The cross-linking yield generated in the probe-mutant complex is the top bar of each pair (grey), and the probe-WT complex is the bottom bar of each pair (black).
[0015] Figure 3 . Figure 3 The yield and selectivity of covalent capture (cross-linking) of mutant KRAS and WT KRAS gene sequences by reactive AP-containing probes (X=Ap in the sequences shown) are shown. The cross-linking reaction and gel electrophoresis analysis were performed as described in Figure 1. The probe sequence was varied in a way that a bulge was formally introduced on the target strand of the probe-target complex. The cross-linking yield generated in the probe-mutant complex is the top bar of each pair (grey), and the cross-linking yield generated in the probe-WT complex is the bottom bar of each pair (black).
[0016] Figure 4 . Figure 4The yield and selectivity of covalent capture (cross-linking) of mutant KRAS and WT KRAS gene sequences by reactive AP-containing probes (X=Ap in the sequences shown) are shown. The cross-linking reaction and gel electrophoresis analysis were performed as described in Figure 1. The probe sequence was altered in a manner that formally introduced a bulge on the probe strand of the probe-target complex. The cross-linking yield generated in the probe-mutant complex is the top bar of each pair (grey), and the cross-linking yield generated in the probe-WT complex is the bottom bar of each pair (black).
[0017] Figure 5A,B FIG5 shows that the formation of two different cross-linked species can be detected in the reaction of probe 12 with a mixture containing different ratios of mutant KRAS and WT KRAS sequences. The cross-linking reaction and gel electrophoresis analysis were performed as described in FIG1. A: Gel electrophoresis analysis of cross-links formed by probe 12 with a mixture of mutant KRAS and wild-type KRAS sequences. The low-yield cross-links formed with the wild-type sequence are clearly distinguished from the high-yield cross-links formed with the mutant KRAS sequence. B: Gel electrophoresis data graph showing the yield of probe-wild-type and probe-mutant cross-links generated by incubating probe 12 with a mixture containing different ratios of wild-type KRAS and mutant KRAS sequences.
[0018] Figure 6 . Figure 6 Scheme 1 illustrates the covalent capture of a target sequence through the reaction of an Ap site in the probe strand with a guanine residue in the target strand.
[0019] Figure 7 . Figure 7 The sequences of the oligonucleotides used in the examples are listed: mutant target nc35C>G (SEQ ID NO: 1); wild-type target (SEQ ID NO: 2); probe 1 (SEQ ID NO: 3); probe 2 (SEQ ID NO: 4); probe 3 (SEQ ID NO: 5); probe 4 (SEQ ID NO: 6); probe 5 (SEQ ID NO: 7); probe 6 (SEQ ID NO: 8); probe 7 (SEQ ID NO: 9); probe 8 (SEQ ID NO: 10); probe 9 (SEQ ID NO: 11); probe 10 (SEQ ID NO: 12); probe 11 (SEQ ID NO: 13); and probe 12 (SEQ ID NO: 14).
[0020] Figure 8 . Figure 8 Shown are the yields of covalent capture (crosslink formation) of various probes with sequences corresponding to the nc35C>G variant (Mut) and wild-type (WT) KRAS gene sequences.
[0021] Fig. 9 . Fig. 9 It is a bar graph comparing the yield and selectivity of covalent capture of mutant KRAS and WT KRAS sequences by various AP-containing probes. The probe-target complex shown is a nc35C>G variant (Mut) of the KRAS gene sequence. The cross-linking yield generated in the probe-mutant complex is shown in the top bar (gray) of each pair, and the cross-linking yield generated in the probe-WT (nc35C instead of G) KRAS sequence is shown in the bottom bar (black) of each pair. The error bar depicts the standard deviation calculated from at least three measurements.
[0022] Fig.10 . Fig.10 The Fe-EDTA footprint is shown, demonstrating that the crosslink generation of probe 12 in duplex W involves attachment at the guanine mutation in the nc35C>G KRAS sequence. In this experiment, the crosslink attachment site appears as the last band (marked by an arrow) before the "ladder" of cleavage products generated by the Fe-EDTA-H2O2 DNA cleavage reagent is interrupted, because cleavage beyond the crosslink generates large, slow-migrating DNA fragments (see the upper part of lane 4) that are attached to the opposite strand (Luce, RA; Hopkins, PB Methods Enzymol. 2001, 340, 396-412). Lane 1: Fe-EDTA cleavage of the uncrosslinked control; Lane 2: 5'- 32 Maxam-Gilbert G specific cleavage (sequencing) reaction on the P-labeled nc35C>G target strand; Lane 3 is 5'- 32 Lane 4 is the hydroxyl radical footprint reaction of the separated probe-target duplex ( 32 P is labeled on the nc35C>G target strand). 32 P-labeled oligodeoxynucleotides were resolved on 20% denaturing polyacrylamide gels and visualized by phosphorphase analysis.
[0023] Fig.11 . Fig.11 The time course of cross-link formation in duplex W is shown. The probe-target duplex W was incubated in sodium acetate buffer (750 mM, pH 5) containing NaCNBH3 (250 mM) at 37°C. Aliquots were removed from the reaction at different times, the DNA was precipitated with ethanol, and stored at -20°C until electrophoresis analysis. The samples were dissolved in formamide loading buffer, loaded on a denaturing 20% polyacrylamide gel, and the DNA fragments were resolved by electrophoresis. 32P-labeled oligodeoxynucleotides were resolved on a 20% denaturing polyacrylamide gel and visualized by phosphorphase analysis. The graph shows the percent cross-linking yield over time.
[0024] Fig.12 . Fig.12 The effect of pH on the yield and selectivity of covalent capture of mutant KRAS and wild-type KRAS gene sequences (duplexes W and X) by probe 12 is shown. Lane 1: labeled probe strand; Lane 2: probe strand treated with piperidine to induce strand cleavage at the Ap site (0.1 M piperidine, 30 min, 95°C); Lane 3: duplex W, sodium acetate (750 mM, pH 5.2) and NaCNBH3 (200 mM); Lane 4: duplex W, HEPES (50 mM, pH 7), NaCl (100 mM) and NaCNBH3 (200 mM); Lane 5: duplex X, sodium acetate (750 mM, pH 5.2) and NaCNBH3 (200 mM); Lane 6: duplex X, HEPES (50 mM, pH 7), NaCl (100 mM) and NaCNBH3 (200 mM).
[0025] Fig.13 . Fig.13 The Fe-EDTA footprinting provides evidence that the cross-link generation of probe 12 in duplex X involves attachment at opposing adenine residues in the wild-type (WT) KRAS sequence. In this experiment, the cross-link attachment site appears as the last band (marked by an arrow) before the "ladder" of cleavage products generated by the Fe-EDTA-H2O2 DNA cleavage reagent is interrupted because cleavage beyond the cross-link generates large, slow-migrating DNA fragments (see the upper part of lane 4) that are attached to the opposing strand (Luce, RA; Hopkins, PB Methods Enzymol. 2001, 340, 396-412). Lane 1: Fe-EDTA cleavage of the uncross-linked control; Lane 2: 5'- 32 Maxam-Gilbert G specific cleavage (sequencing) reaction on the P-labeled WT target strand; Lane 3 is 5'- 32 Lane 4 is the hydroxyl radical footprint reaction of the separated probe-WT duplex ( 32 P is labeled on the wild-type target strand). 32P-labeled oligodeoxynucleotides were resolved on 20% denaturing polyacrylamide gels and visualized by phosphorphase analysis. The probe-target complex is likely to exist in (at least) two different forms (as shown above, left). Crosslink formation in the WT KRAS sequence can be performed by duplexes with bulging adenine residues (upper left) or bulging guanine residues (lower left). Complexes with bulging adenine place the target adenine residue in a potentially favorable crosslink formation arrangement, similar to what is seen in: Imani Nejad, M. et al., Chem Bio Chem. 2017, 18, 1383-1386.
[0026] Fig.14 . Fig.14 This suggests that, while hybridization of nucleic acid strands is reversible, generating unstable probe-target complexes that can lead to signal loss, covalent interstrand crosslinking of probe-target duplexes provides a more stable signal. DETAILED DESCRIPTION
[0027] The terms defined immediately below are more fully defined by reference to the specification as a whole.To the extent necessary to provide descriptive support, the subject matter and / or text of the appended claims are incorporated herein by reference in their entirety.
[0028] definition
[0029] All readers of this written description will understand that the exemplary aspects and embodiments described and claimed herein may suitably be practiced in the absence of any recited feature, element, or step whether specifically disclosed or not disclosed herein.
[0030] The term "a" or "an" entity refers to one or more of the entity; for example, "a probe" should be understood to represent one or more "probes". Therefore, the terms "a (or "an")", "one (kind) or more (kind)" and "at least one / kind" are used interchangeably herein.
[0031] The term "and (and / and) / or (or)" when used herein should be considered to specifically disclose each of the specifically specified features or components with or without the other. Thus, "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (alone) and "B" (alone). Similarly, "and / or" as used in phrases such as "A, B and / or C" is intended to cover each of the following embodiments: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0032] It should be understood that whenever an aspect is described herein with the language "comprising," other similar aspects described with "consisting of" and / or "consisting essentially of" are also provided.
[0033] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure relates. For example, "complementary" base pairs refer to A / T and G / C base pairings unless otherwise specified.
[0034] Numerical ranges include the values that define the range. Even if there is no explicit indication of "and any ranges therebetween" or the like when listing a list of values (i.e., 1, 2, 3, or 4), the present disclosure explicitly includes any ranges between these values, i.e., 1 to 3, 1 to 4, 2 to 4, etc.
[0035] The headings provided herein are for convenience of reference only and are not limitations of the various aspects or aspects of the disclosure which may be had by reference to this patent specification as a whole.
[0036] As used herein, the term "identity", i.e., "percentage of identity" with amino acid sequences or nucleotide sequences disclosed herein, refers to the relationship between two or more nucleotide sequences or between two or more amino acid sequences. When a position in a sequence is occupied by the same nucleic acid base or amino acid in the corresponding position of the comparison sequence, these sequences are said to be "identical" at the position. The "sequence identity" percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid appears in the two sequences, thereby generating the number of "identical" positions. The number of "identical" positions is then divided by the total number of positions in the comparison window and multiplied by 100 to derive the percentage of "sequence identity". The percentage of "sequence identity" is determined by comparing two optimally aligned sequences within the comparison window. In order to optimally align sequences for comparison, the portion of the nucleotide or amino acid sequence in the comparison window may include additions or deletions called spaces, while the reference sequence remains unchanged. The optimal alignment is such an alignment that, even with spaces, can generate as many "identical" positions as possible between the reference sequence and the comparison sequence. The percentage of "sequence identity" between two sequences can be determined using the program "BLAST", available from the National Center for Biotechnology Information, which combines the programs BLASTN (for nucleotide sequence comparisons) and BLASTP (for amino acid sequence comparisons), both of which are based on the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90(12):5873-5877, 1993).
[0037] As used herein, the term "complementary" when referring to nucleic acid molecules is given its standard definition for complementary Watson-Crick base pairing as understood in the art. "Complementarity percentage (%)" can be determined as explained for "identity percentage", but is based on the number of complementary positions when the sense and antisense strands are aligned, rather than on the same position in the alignment.
[0038] The term "nucleic acid" is a well-known term in the art and is used herein to include DNA and RNA. Unless otherwise indicated, "nucleic acid" molecules and "polynucleotides" are used interchangeably. Nucleic acids may contain conventional phosphodiester bonds or unconventional bonds (i.e., amide bonds, such as those found in peptide nucleic acids (PNA)). In some aspects, nucleic acids are DNA. "Isolated" nucleic acids are intended to refer to such nucleic acid molecules that have been removed from their natural environment, such as from a sample of genomic DNA obtained from a subject. Isolated RNA molecules include in vivo or in vitro RNA transcripts of polynucleotides. Isolated polynucleotides or nucleic acids further include such molecules produced synthetically.
[0039] As used herein, the term "engineered" includes the manipulation of nucleic acid or polypeptide molecules by synthetic means (ie, by recombinant techniques, in vitro peptide synthesis, by enzymatic or chemical coupling of peptides, or some combination of these techniques).
[0040] Overview
[0041] Covalent reactions are widely used in bioanalytical chemistry for detecting bioactive metabolites, protein-protein complexes, and proteins with specific catalytic functions. Detection of specific nucleic acid sequences is important in molecular biology and medicine, and covalent cross-linking reactions are likely to enhance selectivity for specific target sequences and prevent probe-target complex denaturation (melting), which can cause signal degradation in typical hybridization-based assays (see, e.g., US20190271029A1, which is incorporated herein by reference in its entirety). Nevertheless, covalent approaches are uncommon in this field, in part due to the lack of simple and reliable reactions for covalently capturing target sequences. Chemically reactive nucleic acid probes are disclosed herein, which hybridize with target sequences comprising 2'-deoxyguanosine (dG) residues and covalently capture the target sequence, such as in cytosine to guanine mutations at position 35 of cancer-driven variants corresponding to human KRAS genes (SEQ ID NO: 15). This approach utilizes reductive amination to generate stable covalent attachments between abasic sites and dG in probe chains. Importantly, it is disclosed that the introduction of non-canonical structures (e.g., bulges and mismatches) into the probe-target duplex can significantly improve the performance of the probe in terms of yield and selectivity in capturing target dG sequences. In certain embodiments, probes containing abasic sites are capable of simultaneously quantitatively detecting sequences with and without dG in a mixture.
[0042] Disclosed herein is the utility of a unique cross-linking reaction designed to expand the library for covalent capture of defined DNA sequences. This process utilizes a reductive amination reaction between the Ap aldehyde group in the probe strand and the exocyclic amino group of a guanine residue in the target sequence to generate a stable covalently cross-linked probe-target complex (Scheme 1; Figure 6 )(Dutta, 2007; Johnson, 2013). The reaction proceeds through the initial equilibrium formation of an imine intermediate, which is then reduced by sodium cyanoborohydride (NaCNBH3) (Borch, 1971) to give N 2 -alkylguanine cross-links (Dutta, 2007; Johnson, 2013). Importantly, it was demonstrated that the introduction of non-canonical structures (such as bulges and mismatches) into the probe sequence of the probe-target duplex significantly increased the yield and selectivity of covalent capture of the target sequence.
[0043] The cross-linked probe-target molecules can be detected by many schemes, such as by typical fluorescence (AP Silverman et al., Chem. Rev. 2006, 106, 3775; JG Wetmur, Crit. Rev. Biochem. Mol. Biol., 1991, 26, 227; S. Tyagi et al., Nat. Biotechnol. 1996, 14, 303; AP Silverman et al., Adv. Clin. Chem. 2007, 43, 79; VV Demidov et al., Trends Biochem. Sci. 2004, 29, 62; L. Hu et al., Biomark. Res. 2014, 2, 3), colorimetry (I. Alexandre et al., Anal. Biochem. 2001, 295, 1) or electrochemical methods (X. Li et al., Anal. Chem. 2006, 78, 6096). In certain aspects, nanopore technology combined with sequence-specific cross-linking chemistry provides high-contrast (digital in nature) signals for single-molecule sensing of nucleic acid sequences.
[0044] A method for producing covalently cross-linked nucleic acid strands.
[0045] Provided herein is a method for producing covalently cross-linked nucleic acid chains. The method includes incubating a hybridized double-stranded nucleic acid molecule comprising: (i) a target chain comprising 2'-deoxyguanosine (dG) to be cross-linked (referred to herein as "target dG"); and (ii) a probe chain at least partially complementary to a baseless (Ap) residue. In certain embodiments, such methods are performed for the purpose of detecting and / or identifying the presence of target dG residues in the target chain. In certain embodiments, the probe chain, the target chain, or both the probe chain and the target chain are DNA molecules. And, in certain embodiments, the target chain comprises, consists essentially of, or consists of, a genomic or mitochondrial DNA from a biological sample taken from an organism. In the hybridized nucleic acid molecule, the Ap residue of the probe chain is located at the 3' position of the nucleotide residue in the probe chain that is directly opposite to the target dG in the target chain. For illustration, the double-stranded nucleic acid sequence:
[0046] Probe strand 5'GCXGG 3'
[0047] Target strand 3'CGACC 5'.
[0048] The C residue in the probe strand (top) is directly opposite to the target dG residue in the target strand (bottom), and the Ap residue (X) in the probe strand is adjacent to the 3' of the C residue in the probe strand that is directly opposite to the target dG residue in the target strand. The incubation of the hybridized double-stranded nucleic acid molecule is to allow the formation of covalent crosslinks between the Ap residue and the target dG of the probe strand, such as those conditions described in more detail elsewhere, thereby producing covalently crosslinked nucleic acid chains. In certain embodiments, incubation occurs in the presence of NaCNBH3. In certain embodiments, incubation occurs at a pH value of less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0. For example, in certain embodiments, incubation occurs at or about pH 5.1, pH 5.2, or pH 5.3. In certain embodiments, incubation occurs at or about 20°C and 42°C, or any specific value in between, such as at or about 24°C and 37°C, or any specific value in between. In certain embodiments, incubation occurs at or about 24°C or 37°C.
[0049] As described herein, the crosslinking of the hybridized nucleic acid molecules can increase their stability. Further, how the hybridized nucleic acid molecules are crosslinked can also produce distinguishable features. For example, in certain embodiments, the crosslinked hybrid double-stranded molecules comprising the crosslinks between the Ap residues of the probe strand and the target dG residues of the target strand are distinguishable from the crosslinked hybrid double-stranded molecules that are identical except for having dC, dA or dT substitutions at the target dG position of the target strand in terms of stability and / or gel mobility. For example, in certain embodiments, the crosslinked hybrid double-stranded molecules comprising the crosslinks between the Ap residues of the probe strand and the target dG residues of the target strand are distinguishable from the crosslinked hybrid double-stranded molecules that are identical except for having dC substitutions at the target dG position of the target strand in terms of stability and / or gel mobility. Such substitutions can indicate a certain allele of a gene (regardless of wild type or mutant), including alleles that can help predict and / or diagnose certain diseases or disease states when identified. In certain embodiments, the presence or absence of dG residues in the target chain can be used to determine potential resistance to treatment and / or the best treatment option for a disease, cancer, tumor, etc. In certain embodiments, the method further comprises detecting covalent crosslinks between the probe chain and the target chain. In certain embodiments, the detection detects and / or identifies the presence of dG residues (target dG) in the target chain. In certain embodiments, the detection is performed by gel electrophoresis, thermal stability monitoring, fluorescence (ie, FRET), electrochemistry, surface plasmon resonance, or a nanopore-based sensor, optionally wherein the detection is performed by a nanopore-based sensor. Such a detection method can provide a qualitative assessment of crosslink formation and / or the type of crosslink formation, and in certain embodiments can also provide quantitative detection of crosslink formation (including the type of crosslink formed).
[0050] A method for detecting the presence or absence of a dG residue at a specific position in a nucleic acid target strand.
[0051] Provided herein is a method for detecting the presence or absence of a dG residue (target dG) at a specific position in a nucleic acid target strand. The method includes incubating a hybridized double-stranded nucleic acid molecule comprising (i) a target strand; and (ii) a probe strand at least partially complementary to a baseless (Ap) residue. In certain embodiments, the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules. And, in certain embodiments, the target strand comprises, for example, a genomic or mitochondrial DNA from a biological sample taken from an organism. As exemplified elsewhere herein, in a hybridized nucleic acid molecule, the Ap residue of the probe strand is located adjacent to the 3' position of the nucleotide residue directly opposite to the specific position in the probe strand for the presence or absence of the target dG residue to be detected in the target strand. The incubation of the hybridized double-stranded nucleic acid molecule is to allow the formation of a covalent cross-link between the Ap residue of the probe strand and the target dG residue (if present), such as under conditions described in more detail elsewhere. In certain embodiments, incubation occurs in the presence of NaCNBH3. In certain embodiments, incubation occurs at a pH value of less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0. For example, in certain embodiments, incubation occurs at or about pH 5.1, pH 5.2, or pH 5.3. In ...
[0052] In certain embodiments, the method further comprises detecting whether the target strand and the probe strand are cross-linked, thereby detecting the presence (Ap residue is cross-linked with the target dG) or absence (Ap residue is not cross-linked with the target dG) of the target dG residue at a specific position in the target strand. In certain embodiments, the covalent cross-linking of the probe strand and the target strand is detected by gel electrophoresis, thermal stability monitoring, fluorescence (i.e., FRET), electrochemistry, surface plasmon resonance, or a nanopore-based sensor, and optionally wherein the covalent cross-linking of the probe strand and the target strand is detected by a nanopore-based sensor. Such a detection method can provide a qualitative assessment of cross-link formation and / or the type of cross-link formation, and in certain embodiments can also provide a quantitative detection of cross-link formation (including the type of cross-link formed). In certain embodiments, the target dG is present at a specific position in the target strand, and a covalent cross-link is formed between the Ap residue in the probe strand and the target dG in the target strand. Therefore, in certain embodiments, the method detects the presence of a dG residue in the target strand. In certain other embodiments, the target dG is not present at a specific position in the target strand, and a covalent cross-link is not formed between the Ap residue in the probe strand and the target dG. Thus, in certain embodiments, the methods detect the absence of dG residues in the target strand.
[0053] A method for detecting the presence of dG residues in a nucleic acid strand.
[0054] Provided herein is a method for detecting the presence of dG residues in a nucleic acid chain. The method includes incubating a hybridized double-stranded nucleic acid molecule, the hybridized double-stranded nucleic acid molecule comprising (i) a target chain comprising a dG residue (target dG) to be detected; and (ii) a probe chain at least partially complementary to a baseless (Ap) residue. In certain embodiments, the probe chain, the target chain, or both the probe chain and the target chain are DNA molecules. In certain embodiments, the target chain is, for example, a genome or mitochondrial DNA from a biological sample taken from an organism. As exemplified elsewhere herein, in a hybridized nucleic acid molecule, the Ap residue of the probe chain is located at the 3' position of a nucleotide residue directly opposite to the target dG residue in the target chain in the immediate vicinity of the probe chain. Incubation is a condition that allows the formation of a covalent cross-link between the Ap residue in the probe chain and the target dG residue in the target chain, such as those conditions described in more detail elsewhere. In certain embodiments, incubation occurs in the presence of NaCNBH3. In certain embodiments, incubation occurs at a pH value of less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0. For example, in certain embodiments, incubation occurs at or about pH 5.1, pH 5.2, or pH 5.3. In ...
[0055] In certain embodiments, the method further comprises detecting the covalent crosslinks between the Ap residue in the probe chain and the target dG of the probe chain and the target chain; thereby detecting the presence of the target dG residue in the target chain. In certain embodiments, the covalent crosslinks of the probe chain and the target chain are detected by gel electrophoresis, thermal stability monitoring, fluorescence (i.e., FRET), electrochemistry, surface plasmon resonance, or nanopore-based sensors, and optionally wherein the covalent crosslinks of the probe chain and the target chain are detected by nanopore-based sensors. Such detection methods can provide a qualitative assessment of crosslink formation and / or the type of crosslink formation, and in certain embodiments can also provide quantitative detection of crosslink formation (including the type of crosslink formed).
[0056] Methods for detecting mutations in wild-type sequences.
[0057] Provided herein are methods for detecting mutations in wild-type sequences. The methods include detecting the presence or absence of a target dG residue at a specific position in a target strand according to any of the methods and using a nucleic acid described above or anywhere else herein. In certain embodiments, the target dG residue is present at a specific position in the target strand and the mutation includes a T→G, A→G, or C→G mutation. In certain other embodiments, the dG residue is absent at a specific position in the target strand and the mutation includes a G→T, G→A, or G→C mutation.
[0058] In certain embodiments, the presence or absence of dG residues in the target strand represents a disease-associated mutation, such as a cancer-associated mutation. In certain embodiments, the presence or absence of dG residues in the target strand can be used to determine potential resistance to treatment and / or the best treatment option for a disease, cancer, tumor, etc.
[0059] Covalently cross-linked, hybridized double-stranded nucleic acid molecules.
[0060] Provided herein are covalently cross-linked hybridized double-stranded nucleic acid molecules. The molecule comprises a probe strand containing an abasic (Ap) residue and a target strand comprising a 2'-deoxyadenosine (dG) residue, wherein as exemplified elsewhere herein, the Ap residue is located at the 3' position of the nucleotide residue directly opposite to the dG residue in the target strand in the immediate vicinity of the probe strand, and the Ap residue is covalently cross-linked with the dG residue in the target strand, and the dG residue in the target strand is directly opposite to the nucleotide residue 3' of the immediate vicinity of the AP residue in the probe strand. In certain embodiments, the nucleic acid molecule is isolated. In certain embodiments, the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules. In certain embodiments, the target strand is, for example, a genomic or mitochondrial DNA from a biological sample taken from an organism.
[0061] In certain embodiments of any of the methods and nucleic acids disclosed above and anywhere herein, the sequence immediately 5' and 3' flanking the Ap residue in the probe strand may be fully complementary to the corresponding sequence in the target strand, or it may be altered so that certain relative residues in the hybridized molecule are mismatched and / or a bulge is formed in the target strand or the probe strand. The sequence, region, segment, etc., including the Ap residue immediately 5' and 3' flanking the Ap residue in the probe strand may be defined as a 5, 6, 7, 8, or 9 nucleotide long segment of the probe strand sequence, i.e., 2, 3, or 4 nucleotides immediately 5' of the Ap residue to 2, 3, or 4 nucleotides immediately 3' of the Ap residue. For example, where X is the Ap residue of the probe strand and Y is other residues of a 5 nucleotide long probe strand segment including the Ap residue immediately 5' and 3' flanking the Ap residue, the sequence may be 5'YYXYY3'. For example, where X is the Ap residue of the probe strand and Y is other residues of a 6-nucleotide long probe strand segment including the Ap residue immediately flanking the Ap residue at 5' and 3', the sequence can be 5'YYXYYY 3' or 5'YYYXYY 3'. For example, where X is the Ap residue of the probe strand and Y is other residues of a 7-nucleotide long probe strand segment including the Ap residue immediately flanking the Ap residue at 5' and 3', the sequence can be 5'YYYXYYY 3' or 5'YYYYXYY 3' or 5'YYXYYYY 3', etc. In certain embodiments, the sequence including the Ap residue immediately flanking the Ap residue at 5' and 3' in the probe strand comprises, consists essentially of, or consists of: (i) fully complementary base pairing between the probe strand and the target strand (e.g., probe 1 disclosed elsewhere herein) at positions other than the Ap residue positions. In other embodiments, the sequences immediately 5' and 3' to the Ap residue in the probe strand comprise, consist essentially of, or consist of: (ii) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG (e.g., probe 2 disclosed elsewhere herein), wherein in certain such embodiments, the nucleotide residue immediately 5' to the Ap residue on the probe strand is A, T, or G; (iii) a mismatch between the nucleotide residue immediately 3' to the Ap residue on the probe strand and the target dG (e.g., probe 3 disclosed elsewhere herein); , 4 and 5); (iv) a sequence that forms a bulge in a target strand (e.g., probes 6, 7 and 8 disclosed elsewhere herein); and / or (v) a sequence that forms a bulge in a probe strand (e.g., probes 9, 10, 11 and 12 disclosed elsewhere herein), wherein in certain such embodiments, the probe strand sequence that forms the bulge in the probe strand comprises an insertion of a nucleotide that does not have a corresponding residue in the target strand sequence immediately 3' to the Ap residue in the probe strand, optionally wherein the insertion is an insertion of A.It has been found that in certain embodiments, the use of probe strand sequences consistent with (ii), (iii), (iv) or (v) can provide benefits over the use of probe strand sequences with fully complementary base pairing. In certain embodiments, such benefits can be an increased yield of the cross-linking reaction and / or an increased selectivity of the Ap residue for the target dG residue relative to other cross-link formations.
[0062] In certain embodiments of any of the methods and nucleic acids disclosed above and anywhere herein: (i) the target strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 5' to the target dG residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 3' to the target dG residue; and / or (ii) the probe strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 5' to the Ap residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 3' to the Ap residue. In certain embodiments: (i) the target strand comprises no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides located 5' to the target dG residue and no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides located 3' to the target dG residue; and / or (ii) the probe strand comprises no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides located 5' to the Ap residue and no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides located 3' to the Ap residue.In certain embodiments: (i) the length of the target strand is at least or at least about 100, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 nucleotides; (ii) the length of the probe strand is less than or about 100, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 nucleotides. or (iii) the hybridizing nucleic acid molecule comprises a hybridizing sequence portion comprising the Ap residue of the probe strand and the target dG residue of the target strand that is at least or at least about 100 nucleotides long, is or is about 100 nucleotides long, or between or about any of the following: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous nucleotides in length. As indicated herein, the probe strand is at least partially complementary to the target strand to allow the probe strand to hybridize to the target strand, particularly in the region of the probe strand immediately flanking the 5' and 3' of the Ap residue, including the Ap residue, and the region of the specific position of the target dG (whether present or absent) in the target strand. In certain embodiments, the hybridized portion containing the Ap residue of the probe strand and the target dG residue position of the target strand, excluding the position of the Ap residue, has a complementarity of at least or at least about less than, less than or about less than, or between or between about any of the following: 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or has 100% complementarity.
[0063] In certain embodiments of any of the methods and nucleic acids disclosed above and anywhere herein, the probe strand and / or target strand comprises a terminal extension covalently attached to the 5' end, the 3' end, or both the 5' end and the 3' end of the strand. In certain embodiments, the terminal extension is covalently attached to the 3' end of the strand and is selected from the group consisting of: poly(dC) (3-33) (poly(dC) (3-33) ), poly(dG) (3-33) (poly(dG) (3-33) ), poly(dA) (3-33) (poly(dA) (3-33) ), poly(dT) (3-33)(poly(dT) (3-33) ) and poly(dN) (3-33) (poly(dN) (3-33) ), wherein N is any combination of 2'-deoxycytosine, 2'-deoxyguanosine, 2'-deoxyadenosine, thymine, abase, inosine, xanthosine, 7-methylguanosine, dihydrouridine or 5-methylcytidine.
[0064] In certain specific, non-limiting exemplary embodiments, the cross-linking reaction described above is applied to detect a DNA sequence corresponding to a C→G mutation at position 35 in the non-coding strand of the human KRAS gene sequence (nc35C>G, which corresponds to a c35G→C translocation in the coding strand of the KRAS gene) (Riely, 2008). This genetic variant results in a cancer-driving G12A substitution in the KRAS protein (Knickelbein, 2015). It was found that the dG-AP cross-linking reaction can be used for the selective covalent capture of mutant KRAS sequences.
[0065] The cancer driver KRAS gene sequence is selectively covalently captured by the reaction of the AP-containing probe strand with the guanine residues in the target strand.
[0066] Disclosed herein is a probe wherein the Ap site selectively crosslinks with the guanine mutation in the nc35C>G KRAS gene sequence. Probe sequence 1 (FIG. 1A and Figure 2 ) was designed to position the Ap site 1 nt away from the target guanine residue in the probe-target complex. This design was based on previous observations that the Ap aldehyde can form covalent crosslinks with guanine residues on the opposite strand that are offset 1 nt to the 5' side of the Ap site (duplex A, Figure 1) (Dutta, 2007; Johnson, 2013). This approach further recognized that the addition of a water-compatible hydride reducing agent, NaCNBH3, to the crosslinking reaction could potentially lead to the formation of a covalent crosslink via a reductive amination reaction (Scheme 1; Figure 6 (Johnson, 2013) produces chemically stable dG-Ap interstrand crosslinks in appreciable (~20%) yields. At the time of the current study, the extent and universality of this interstrand DNA crosslinking reaction was unknown and had only been examined previously in two different sequence contexts (Johnson, 2013; Dutta, 2007; and Imani-Nejad, 2019).
[0067] The 21 nt 5'-deoxyuracil oligonucleotide containing the reactive Ap site was prepared by treating the corresponding 2'-deoxyuracil-containing oligonucleotide with the enzyme uracil DNA glycosylase (UDG). 32P-labeled probe strand 1 (Varshney, 1991; Lindahl, 1977; and Stuart, 1987). Installation of the Ap residue in the probe was confirmed by piperidine-induced cleavage at the Ap site to generate a short 10 nt 32P-labeled fragment (Fig. 1A, lane 2) (McHugh, 1995; Stuart, 1987). 32 The P-labeled AP-containing probe strand was incubated with the mutant KRAS target sequence in sodium acetate buffer (0.75 M, pH 5.2) containing NaCNBH3 (200 mM). 32 The P-labeled products were analyzed by electrophoresis on a denaturing 20% polyacrylamide gel. The cross-linked 21 bp probe-target complex was detected as a characteristic slow-migrating band with a yield of 7.2 ± 0.9% (Dutta, 2007; Johnson, 2013; Hartley, 1993) (Figure 1A). Incubation of the AP-containing probe strand with the wild-type (WT) KRAS sequence produced a slow-migrating cross-linked band at a significantly lower yield (1.7 ± 1.1%). Thus, the signal provided by probe 1 for the mutant sequence (duplex A, Figure 1A) was 4.2 times higher than that provided for the WT sequence (duplex B, Figure 1A), and the cross-linking yield between the mutant and WT sequences differed by 5.5%. The source of the background signal caused by the cross-linking generation in the duplex lacking the target guanine residue will be discussed further below.
[0068] Introducing mismatches into the probe sequence in the probe-target complex can increase the selectivity and yield of covalent capture of mutant KRAS sequences.
[0069] Based on the observed selective detection of mutant KRAS sequences by AP-containing probe 1, it was theorized that changes in the probe sequence that formally introduce non-canonical structures (e.g., mismatches and bulges) into the probe-target complex would improve the selectivity and yield of covalent crosslinks with mutant KRAS target sequences. Furthermore, it has been previously demonstrated that mismatches in the probe-target complex significantly improve the ability of the AP-containing probe strand to selectively detect T→A mutations in the BRAF gene sequence (Imani-Nejad, 2017). We first examined probe-mutant complexes (duplex C, Figure 2) produced a G / A mismatch at the target guanine residue in the Ap probe. However, this change in the Ap probe sequence significantly reduced the yield and selectivity for detecting mutant KRAS sequences (4.2±0.6% cross-linking yield with the mutant vs. 2.6±0.4% yield for the WT sequence). The effect of mismatches located on the 3' side of the Ap site distal to the target guanine residue in the mutant sequence (probes 3-5) was next examined. It was found that mismatches in this position significantly improved the yield and selectivity of probe cross-linking to the mutant sequence relative to the WT sequence (duplex EJ, Figure 2 In this series, the best performance was obtained with probe 5 that generated an A / C mismatch (cross-linking yield of 36.1 ± 1.2% in probe-mutant duplex I and 5.1 ± 0.4% in probe-WT duplex J, corresponding to 7.1-fold selectivity for the target sequence and a 31% difference in cross-linking yield between mutant and WT sequences).
[0070] Selectivity and yield of covalent capture of mutant KRAS sequences were achieved by AP-containing probe strands that introduced a formal bulge into the probe-target complex.
[0071] The performance of AP-containing probes 6 and 7 was examined, in which one or two base deletions resulted in probe-target complexes (duplex KN, Figure 3 ) formally produce a 1nt or 2nt bulge on the target strand in ). These probes produce crosslinks with good yields and are more selective for mutant KRAS sequences than for WT, but both yield and selectivity are lower than the best 3'-mismatch probes discussed above ( Figure 2 , probe 5, duplex I / J). Designed for use in probe-target complexes (duplex O / P, Figure 3 ) provided cross-linking yields and selectivities similar to those in the probe-target complex (duplex M / N, Figure 3 ) produces a formal 2nt bulge on the target strand.
[0072] A series of AP-containing probes 9-12 ( Figure 4 With T, C, or G inserted into the probe, the yield of crosslinks formed with the mutant KRAS sequence was modest, and the selectivity for the mutant sequence relative to the WT sequence was rather poor (duplex QV, Figure 4On the other hand, insertion of the A residue into the probe (duplex W / X) provided the best overall yield of probe-mutant crosslink formation (57.7±1%), good selectivity (5.7-fold), and a large yield difference (48%) compared to the crosslink formation produced with the WT sequence. A representative gel electrophoresis analysis of this crosslinking reaction is shown in FIG1B .
[0073] The probe captures mutant KRAS sequences by rapidly reacting with the mutant guanine residue at position 35 and does not require strict temperature control.
[0074] Several key features of probe 12 that generate crosslinks in duplexes W and X were examined. Iron-EDTA footprinting experiments (Luce, 2001; Johnson, 2013) correctly located the probe-mutant duplex crosslink attachment site at the guanine mutation in the nc35C>G sequence ( Fig.10 The reductive amination reaction rapidly produced crosslinks in duplex W, yielding >40% yield within 4 hours and reaching a final yield of approximately 58% in approximately 8 hours ( Fig.11 The cross-linking reaction in duplex W was better at pH 5.2 than at pH 7 in terms of both signal intensity (yield) and selectivity for mutant sequences over WT ( Fig.12 ). This type of pH dependence is typical for reductive amination reactions (Borch, 1972). It was further demonstrated that strict temperature control is not required for successful use of these probes. Specifically, it was demonstrated that the pH dependence was not significantly different when the reactions were performed at 37°C (standard conditions described above) or at room temperature (24°C; Figure 4 ), the yield and selectivity of probe 12 for the mutant sequence relative to the WT sequence were comparable.
[0075] The origin of the “background” crosslinks generated in WT duplex X, which lacks the target G residue at position 35, has also been considered. It is thought that the crosslinks in duplex X may arise from a unique process involving a low-yield reaction between the Ap site and the directly opposing A residue (Price, 2014). Indeed, Fe-EDTA footprinting reactions on isolated crosslinks generated in duplex X provide evidence for this hypothesis ( Fig.13 ).
[0076] Simultaneous quantitative detection of mutant and wild-type KRAS sequences in a mixture.
[0077] Disclosed herein is the ability to selectively capture (e.g., with probe 12) mutant KRAS sequences in a mixture containing different portions of mutant and WT sequences. It was demonstrated that the cross-linked duplexes produced by the reaction of the probe with the mutant and WT sequences can be completely separated by gel electrophoresis (FIG. 5A). This is accomplished by allowing the cross-linked duplexes to further enter the gel. Under these experimental conditions, gel electrophoresis can be used to measure the relative amounts of mutant and WT KRAS sequences in the mixture separately and simultaneously (FIG. 5B). The separation of the signals produced by the cross-linking formation with the mutant and WT sequences enables the mutant KRAS target sequence to be detected without significant background signal (FIG. 5B).
[0078] Thus, disclosed above is a novel hybridization-induced programmable cross-linking reaction for sequence-selective covalent capture of nucleic acids. Reactive cross-linking probes are prepared from inexpensive commercial reagents in a simple one-step procedure and achieve precise specificity for a particular target sequence under isothermal assay conditions that do not require strict temperature control. The utility of these chemically reactive AP-containing probes has been demonstrated for covalent capture of DNA sequences corresponding to the nc35C>G mutation in the human KRAS gene sequence. The covalent cross-linking reaction produces a chemically stable probe-target complex that is immune to thermal denaturation (Johnson, 2013; Catalano, 2015; Imani-Nejad, 2019). In particular, the introduction of non-canonical mismatches and bulged structures into the probe-target duplex significantly improves the performance in terms of both signal intensity (yield) and selectivity for mutant KRAS sequences relative to wild-type sequences. Gel electrophoresis analysis of certain probes containing abasic sites enables simultaneous quantitative detection of mutant and wild-type KRAS sequences in a mixture without background interference (Figure 5). Although the three-dimensional structure of these probe-target duplexes is unknown, mismatches and bulges create dynamic complexes (Rossetti, 2015; John, 2004), which may better accommodate the distortions required for covalent crosslink formation. 32 P-labeled probe strands, gel electrophoresis analysis, and phosphorimaging are used to detect cross-linked probe-target complexes; however, it is expected that such sequence-selective covalent capture may be adapted for use with other methods, including capillary electrophoresis (Durney, 2015), nanopore technology (Zhang, 2015; Shi, 2018; Imani-Nejad, 2017), fluorescence spectroscopy (Silverman, 2006; Demidov, 2004), UV-visible spectroscopy (Alexandre, 2001), and / or electrochemical detection (Li, 2006).
[0079] Example paragraph
[0080] Paragraph 1. A method for producing covalently cross-linked nucleic acid chains, the method comprising incubating a hybridized double-stranded nucleic acid molecule, the hybridized double-stranded nucleic acid molecule comprising: (i) a target chain comprising a segment of a nc35C>G mutant human KRAS gene sequence, the nc35C>G mutant human KRAS gene sequence comprising a mutant G nucleotide residue of the nc35C>G mutation; and (ii) an at least partially complementary probe chain comprising an abasic (Ap) residue, wherein in the hybridized nucleic acid molecule, the Ap residue of the probe chain is located adjacent to the mutant G nucleotide residue of the nc35C>G mutation in the probe chain. at the 3' position of the directly opposite nucleotide residue, and wherein the incubation occurs under conditions that allow covalent cross-linking to form between the Ap residue of the probe strand and the mutant G nucleotide residue of the nc35C>G mutant KRAS gene sequence; thereby producing a covalently cross-linked nucleic acid strand; optionally, wherein the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules; optionally, wherein the target strand comprises genomic or mitochondrial DNA; optionally, wherein the incubation occurs in the presence of NaCNBH3; and / or optionally, wherein the incubation occurs at a pH value of less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5 and optionally greater than or greater than about pH 4.5 or greater than or greater than about pH 5.0; and optionally, wherein the incubation occurs at or about pH 5.1, pH 5.2 or pH 5.3.
[0081] Paragraph 2. A method as described in paragraph 1, wherein the probe strand sequence that hybridizes to the region of the nc35C>G mutation sequence in the target strand comprises: 5'GCXGG; 5'GAXGG; 5'GCXTG; 5'GCXCG; 5'GCXAG; 5'GCXGC; 5'GCXCG; 5'GCXAC; 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG, wherein X is the Ap residue, and wherein in the hybrid molecule, the probe strand The Ap residue is located at the 3' position of the nucleotide residue in the probe chain that is directly opposite to the mutant G nucleotide residue of the nc35C>G mutation; optionally, the sequence of the probe chain that hybridizes to the region of the nc35C>G mutation sequence in the target chain contains: 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG; and optionally, the sequence of the probe chain that hybridizes to the region of the nc35C>G mutation sequence in the target chain contains 5'GCXAGG.
[0082] Paragraph 3. A method as described in paragraph 1 or 2, wherein: (i) the target strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 5' of the mutant G nucleotide residue of the nc35C>G mutation and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 3' of the mutant G nucleotide residue of the nc35C>G mutation , 20, 25, 30, 40 or 50 nucleotides; and / or (ii) the probe strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 5' to the Ap residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 3' to the Ap residue; Optionally, wherein: (i) the target strand comprises no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50 or 100 nucleotides 5' of the mutant G nucleotide residue of the nc35C>G mutation and no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50 or 100 nucleotides 3' of the mutant G nucleotide residue of the nc35C>G mutation. and / or (ii) the probe strand comprises no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50 or 100 nucleotides 5' to the Ap residue and no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50 or 100 nucleotides 3' to the Ap residue.
[0083] Paragraph 4. The method of paragraph 3, wherein: (i) the length of the target strand is at least or at least about 100 nucleotides or less, is or is about 100 nucleotides or less, or is between or about any of the following: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides;
[0084] (ii) the length of the probe strand is less than or less than about, is or is about, or is between or about any of the following: 100, 90, 80, 70, 60, 50, 40, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, or 12 nucleotides; and / or (iii) the hybridized nucleic acid molecule comprises an A comprising the probe strand. The length of the sequence portion that hybridizes to the p residue and the mutant G nucleotide residue of the nc35C>G mutation of the target strand is at least or at least about less than, is or is about less than, or between or about any of the following: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90 or 100 contiguous nucleotides.
[0085] Paragraph 5. A method as described in paragraph 4, wherein the hybridized portion containing the Ap residue of the probe chain and the mutant G nucleotide residue of the nc35C>G mutation of the target chain, excluding the position of the Ap residue, has a complementarity of at least or at least about less than, less than or about less than, or between or between about any of the following: 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or has 100% complementarity.
[0086] Paragraph 6. A method as described in paragraph 1, wherein the probe strand comprises, consists essentially of, or consists of: SEQ ID NO: 3 or a fragment thereof comprising 5'GCXGG; SEQ ID NO: 4 or a fragment thereof comprising 5'GAXGG; SEQ ID NO: 5 or a fragment thereof comprising 5'GCXTG; SEQ ID NO: 6 or a fragment thereof comprising 5'GCXCG; SEQ ID NO: 7 or a fragment thereof comprising 5'GCXAG; SEQ ID NO: 8 or a fragment thereof comprising 5'GCXGC; SEQ ID NO: 9 or a fragment thereof comprising 5'GCXCG; SEQ ID NO: 10 or a fragment thereof comprising 5'GCXAC; SEQ ID NO: 11 or a fragment thereof comprising 5'GCXTGG; SEQ ID NO: 12 or a fragment thereof comprising 5'GCXCGG; SEQ ID NO: 13 or a fragment thereof comprising 5'GCXGGG; or SEQ ID NO: 14 or a fragment thereof comprising 5'GCXAGG, wherein X is said Ap residue; optionally, wherein said probe strand comprises, consists essentially of, or consists of the sequence TTGGAGCTGCXAGGCGTAGGCA (SEQ ID NO: 14) or a fragment thereof comprising 5'GCXAGG.
[0087] Paragraph 7. A method as described in any of paragraphs 1 to 6, wherein the yield of covalently cross-linked nucleic acid chains produced by the method is greater than the yield of covalently cross-linked nucleic acid chains produced by the method except that the target chain comprises a wild-type human KRAS gene sequence instead of the nc35C>G mutation sequence.
[0088] Paragraph 8. The method of any of paragraphs 1 to 7, wherein the yield of covalently cross-linked nucleic acid chains obtained and / or the observed selectivity relative to the wild-type KRAS gene sequence from using a probe strand comprising 5'GAXGG, 5'GCXTG, 5'GCXCG, 5'GCXAG, 5'GCXGC, 5'GCXCG, 5'GCXAC, 5'GCXTGG, 5'GCXCGG, 5'GCXGGG or 5'GCXAGG is greater than using an equivalent probe strand comprising 5'GCXGG; optionally, wherein the yield of covalently cross-linked nucleic acid chains obtained and / or the observed selectivity relative to the wild-type KRAS gene sequence from using a probe strand comprising, consisting essentially of, or consisting of the following sequences is greater than using an equivalent probe strand comprising, consisting essentially of, or consisting of the sequence SEQ ID NO: 3 or a fragment thereof comprising 5'GCXGG. NO:6 or a fragment thereof comprising 5'GCXCG; SEQ ID NO:7 or a fragment thereof comprising 5'GCXAG; SEQ ID NO:8 or a fragment thereof comprising 5'GCXGC; SEQ ID NO:9 or a fragment thereof comprising 5'GCXCG; SEQ ID NO:10 or a fragment thereof comprising 5'GCXAC; SEQ ID NO:11 or a fragment thereof comprising 5'GCXTGG; SEQ ID NO:12 or a fragment thereof comprising 5'GCXCGG; SEQ ID NO:13 or a fragment thereof comprising 5'GCXGGG; or SEQ ID NO:14 or a fragment thereof comprising 5'GCXAGG.
[0089] Paragraph 9. A method for detecting the presence of a nc35C>G [[c35G>C]] cancer driver mutation in a human KRAS gene, the method comprising incubating a hybridized double-stranded DNA molecule (dsDNA), the hybridized double-stranded DNA molecule comprising: (i) a target strand comprising a segment of a KRAS gene sequence, the segment comprising a nucleotide residue corresponding to residue 35 in the coding strand of the human KRAS gene (SEQ ID NO: 15); and (ii) an at least partially complementary probe strand comprising an abasic (Ap) residue, wherein in the hybrid molecule, the Ap residue of the probe strand is located at a position immediately 3' to a nucleotide residue in the probe strand that is directly opposite to the nucleotide residue in the target strand that corresponds to residue 35 in the coding strand of the human KRAS gene (SEQ ID NO: 15), and wherein the incubation is performed at a time point that allows the Ap residue in the probe strand and the nc35C>G and detecting the covalent cross-link between the Ap residue in the probe strand and the mutant G nucleotide residue in the nc35C>G KRAS mutant gene, thereby detecting the presence of the KRAS gene mutation; optionally, wherein the formation of the covalent cross-link between the Ap residue in the probe strand and the mutant G nucleotide residue in the KRAS mutant gene occurs selectively compared to the C nucleotide residue at the same position in the wild-type KRAS gene; optionally, wherein the target strand is genomic or mitochondrial DNA; optionally, wherein the covalent cross-link between the probe strand and the target strand is detected by gel electrophoresis, thermal stability monitoring, fluorescence (i.e., FRET), electrochemistry, surface plasmon resonance, or a nanopore-based sensor; optionally, wherein the incubation occurs in the presence of NaCNBH3; and / or optionally, wherein the incubation is at less than or less than about pH 7, less than or less than about pH 6.0, or less than or less than about pH 5.5, and optionally greater than or greater than about pH 4.5, or greater than or greater than about pH 5.5. and optionally, wherein the incubating occurs at or about pH 5.1, pH 5.2 or pH 5.3.
[0090] Paragraph 10. A method as described in paragraph 9, wherein the detection of covalent cross-linking of the probe chain and the target chain comprising the mutant G nucleotide residue of the nc35C>G KRAS mutant gene is compared with the detection of covalent cross-linking of the probe chain and the target chain comprising the C nucleotide residue of the wild-type KRAS gene; optionally, wherein the formation and / or detection of cross-linked probe-mutant target chain molecules and cross-linked probe-wild-type target chain molecules are performed simultaneously; optionally, wherein the formation and / or detection of probe-mutant target chain and probe-wild-type target chain are performed within the same sample; and / or optionally, wherein the detection and / or comparison is performed quantitatively.
[0091] Paragraph 11. The method of paragraph 9 or 10, wherein the sequence of the probe strand that hybridizes to the region of the nucleotide residue in the target strand corresponding to residue 35 in the coding strand of the KRAS gene (SEQ ID NO: 15) comprises: 5'GCXGG; 5'GAXGG; 5'GCXTG; 5'GCXCG; 5'GCXAG; 5'GCXGC; 5'GCXCG; 5'GCXAC; 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG, wherein X is an Ap residue, wherein in the hybrid molecule, the Ap residue of the probe strand is located at a position 3' to the nucleotide residue in the probe strand that is immediately opposite to the nucleotide residue in the coding strand of the KRAS gene (SEQ ID NO: 15) of the target strand; optionally, wherein the Ap residue of the probe strand hybridizes to the region of the nucleotide residue in the target strand corresponding to residue 35 in the coding strand of the KRAS gene (SEQ ID NO: 15) of the target strand. The sequence of the probe chain that hybridizes to the region of the nucleotide residues corresponding to residue 35 in the coding strand of the target strand (SEQ ID NO: 15) comprises: 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG; and optionally, wherein the sequence of the probe chain that hybridizes to the region of the nucleotide residues corresponding to residue 35 in the coding strand of the human KRAS gene (SEQ ID NO: 15) comprises 5'GCXAGG.
[0092] Paragraph 12. The method of any one of paragraphs 9 to 11, wherein: (i) the target strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 5' to the nucleotide residue corresponding to residue 35 in the coding strand of the KRAS gene (SEQ ID NO: 15) and a residue corresponding to residue 40 in the coding strand of the KRAS gene (SEQ ID NO: 15). NO:15); and / or (i) the probe strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 3' to the nucleotide residue 35 in the coding strand of Ap residue 15; and / or (i) the probe strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 5' to the Ap residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 3' to the Ap residue; optionally, wherein: (i) the target strand comprises a polypeptide corresponding to the KRAS gene (SEQ ID No more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50 or 100 nucleotides 5' of the nucleotide residue of residue 35 in the coding strand of the gene encoding KRAS (SEQ ID NO:15) no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides 3' of the nucleotide residue 35 in the coding strand of the polypeptide of the invention; and / or (ii) the probe strand comprises no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides 5' of the Ap residue and no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides 3' of the Ap residue.
[0093] Paragraph 13. The method of paragraph 12, wherein: (i) the length of the target strand is at least or at least about 100 nucleotides or less, is or is about 100 nucleotides or less, or is between or about any of the following: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides; (ii) the length of the probe strand is less than or less than or less than about, is or is about, or is between or between about any of: 100, 90, 80, 70, 60, 50, 40, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13 or 12 nucleotides; and / or (iii) the hybridizing nucleic acid molecule comprises an Ap residue of the probe strand and a target strand corresponding to the human KRAS gene (SEQ ID NO: 1 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous nucleotides in length.
[0094] Paragraph 14. The method of paragraph 13, wherein the hybridized portion containing the Ap residue of the probe strand and the nucleotide residue of the target strand corresponding to residue 35 in the coding strand of the human KRAS gene (SEQ ID NO: 15) has, excluding the position of the Ap residue, at least or about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% complementarity, or has 100% complementarity.
[0095] Paragraph 15. The method of paragraph 9, wherein the probe strand comprises, consists essentially of, or consists of: SEQ ID NO: 3 or a fragment thereof comprising 5'GCXGG; SEQ ID NO: 4 or a fragment thereof comprising 5'GAXGG; SEQ ID NO: 5 or a fragment thereof comprising 5'GCXTG; SEQ ID NO: 6 or a fragment thereof comprising 5'GCXCG; SEQ ID NO: 7 or a fragment thereof comprising 5'GCXAG; SEQ ID NO: 8 or a fragment thereof comprising 5'GCXGC; SEQ ID NO: 9 or a fragment thereof comprising 5'GCXCG; SEQ ID NO: 10 or a fragment thereof comprising 5'GCXAC; SEQ ID NO: 11 or a fragment thereof comprising 5'GCXTGG; SEQ ID NO: 12 or a fragment thereof comprising 5'GCXCGG; SEQ ID NO: 13 or a fragment thereof comprising 5'GCXGGG; or SEQ ID NO: 14 or a fragment thereof comprising 5'GCXAGG, wherein X is said Ap residue; optionally, wherein said probe strand comprises, consists essentially of, or consists of the sequence TTGGAGCTGCXAGGCGTAGGCA (SEQ ID NO: 14) or a fragment thereof comprising 5'GCXAGG.
[0096] Paragraph 16. The method of any of paragraphs 9 to 15, wherein the yield of covalently cross-linked nucleic acid chains obtained and / or the observed selectivity relative to the wild-type KRAS gene sequence is greater from using a probe strand comprising 5'GAXGG, 5'GCXTG, 5'GCXCG, 5'GCXAG, 5'GCXGC, 5'GCXCG, 5'GCXAC, 5'GCXTGG, 5'GCXCGG, 5'GCXGGG or 5'GCXAGG than from using an equivalent probe strand comprising 5'GCXGG; optionally, wherein the yield of covalently cross-linked nucleic acid chains obtained and / or the observed selectivity relative to the wild-type KRAS gene sequence is greater from using a probe strand comprising, consisting essentially of, or consisting of the following sequences than from using an equivalent probe strand comprising, consisting essentially of, or consisting of the sequence SEQ ID NO:3. NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; or SEQ ID NO: 14.
[0097] Paragraph 17. A single-stranded nucleic acid probe for detecting the nc35C>G mutation in the human KRAS gene sequence, the probe comprising the sequence: 5'GCXGG; 5'GAXGG; 5'GCXTG; 5'GCXCG; 5'GCXAG; 5'GCXGC; 5'GCXCG; 5'GCXAC; 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG, wherein X is an Ap residue, optionally wherein the probe comprises the sequence: 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG; optionally wherein the probe comprises the sequence 5'GCXAGG; and / or optionally wherein the probe is a DNA molecule.
[0098] Paragraph 18. The probe of paragraph 17, wherein the probe comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 5' to the Ap residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 3' to the Ap residue; optionally, wherein the probe comprises no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides 5' to the Ap residue and no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides 3' to the Ap residue.
[0099] Paragraph 19. The probe of paragraph 17 or 18, wherein the length of the probe is less than or about less than, is or is about less than, or between or about any of the following: 100, 90, 80, 70, 60, 50, 40, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13 or 12 nucleotides.
[0100] Paragraph 20. A probe as described in any of paragraphs 17 to 19, wherein the probe is capable of hybridizing to a region of a nc35C>G mutant human KRAS gene sequence comprising a nc35C>G mutation; optionally, wherein the probe chain comprises a contiguous sequence of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 25, 30, 40 or 50 nucleotides, wherein the contiguous sequence, except for the position of the Ap residue, has at least or at least about less than, less than or about less than, or between or between about any of the following: 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or has 100% complementarity with the nc35C>G mutant human KRAS gene sequence comprising a nc35C>G point mutation site.
[0101] Paragraph 21. A probe as described in any of paragraphs 17 to 20, wherein the probe comprises, consists essentially of, or consists of: SEQ ID NO: 3 or a fragment thereof comprising 5'GCXGG; SEQ ID NO: 4 or a fragment thereof comprising 5'GAXGG; SEQ ID NO: 5 or a fragment thereof comprising 5'GCXTG; SEQ ID NO: 6 or a fragment thereof comprising 5'GCXCG; SEQ ID NO: 7 or a fragment thereof comprising 5'GCXAG; SEQ ID NO: 8 or a fragment thereof comprising 5'GCXGC; SEQ ID NO: 9 or a fragment thereof comprising 5'GCXCG; SEQ ID NO: 10 or a fragment thereof comprising 5'GCXAC; SEQ ID NO: 11 or a fragment thereof comprising 5'GCXTGG; SEQ ID NO: 12 or a fragment thereof comprising 5'GCXCGG; SEQ ID NO: 13 or a fragment thereof comprising 5'GCXGGG; or SEQ ID NO: 14 or a fragment thereof comprising 5'GCXAGG, wherein X is said Ap residue; optionally, wherein said probe comprises, consists essentially of, or consists of the sequence TTGGAGCTGCXAGGCGTAGGCA (SEQ ID NO: 14) or a fragment thereof comprising 5'GCXAGG.
[0102] Paragraph 22. The probe of any of paragraphs 17 to 21, wherein the probe comprises a detectable label; optionally, wherein the probe is radiolabeled, and optionally, wherein the radiolabel is 32P; or optionally, wherein the probe comprises a terminal extension covalently attached to the 5' end, the 3' end, or both the 5' end and the 3' end of the probe; and optionally, wherein the terminal extension is covalently attached to the 3' end of the probe and is selected from the group consisting of poly(dC) (3-33), poly(dG) (3-33), poly(dA) (3-33), poly(dT) (3-33), and poly(dN) (3-33), wherein N is any combination of 2'-deoxycytidine, 2'-deoxyguanosine, 2'-deoxyadenosine, thymine, abasic, inosine, xanthosine, 7-methylguanosine, dihydrouridine, or 5-methylcytidine.
[0103] Paragraph 23. A covalently cross-linked hybrid double-stranded nucleic acid molecule, the covalently cross-linked hybrid double-stranded nucleic acid molecule comprising: (i) a target chain comprising a segment of a nc35C>G mutant human KRAS gene sequence segment containing a mutant G nucleotide residue containing a nc35C>G point mutation site; (ii) an at least partially complementary probe chain comprising an abasic (Ap) residue, wherein in the hybridized molecule, the Ap residue of the probe chain is located at the 3' position of the nucleotide residue in the probe chain that is directly opposite to the mutant G nucleotide residue of the nc35C>G point mutation; wherein the Ap residue of the probe chain is covalently cross-linked to the mutant G nucleotide residue of the nc35C>G mutant KRAS gene sequence; optionally, wherein the nucleic acid molecule is isolated.
[0104] Paragraph 24. The cross-linked nucleic acid molecule of paragraph 23, wherein the probe strand, the target strand, or both the probe strand and the target strand are DNA molecules; optionally, wherein the target strand is genomic or mitochondrial DNA.
[0105] Paragraph 25. A cross-linked nucleic acid molecule as described in paragraph 24, wherein the probe strand sequence that hybridizes to the region of the nc35C>G point mutation site in the target strand comprises: 5'GCXGG; 5'GAXGG; 5'GCXTG; 5'GCXCG; 5'GCXAG; 5'GCXGC; 5'GCXCG; 5'GCXAC; 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG, wherein X is the Ap residue, and wherein in the hybridized molecule, the The Ap residue of the probe chain is located at the 3' position of the nucleotide residue in the probe chain that is directly opposite to the G nucleotide residue of the nc35C>G point mutation; optionally, the sequence of the probe chain that hybridizes to the region of the nc35C>G point mutation site in the target chain contains: 5'GCXTGG; 5'GCXCGG; 5'GCXGGG; or 5'GCXAGG; and optionally, the sequence of the probe chain that hybridizes to the region of the nc35C>G point mutation site in the target chain contains 5'GCXAGG.
[0106] Paragraph 26. A cross-linked nucleic acid molecule as described in paragraph 24 or 25: wherein: (i) the target strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 5' of the nc35C>G point mutation and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 3' of the nc35C>G point mutation and / or (ii) the probe strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 5' of the Ap residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 3' of the Ap residue.
[0107] 70, 60, 70, 80, 90, or 100 nucleotides in length; and (ii) the length of the probe strand is less than or about 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 100 nucleotides. and / or (iii) the hybridized nucleic acid molecule comprises a hybridized portion comprising the Ap residue of the probe strand and the nc35C>G point mutation site of the target strand, the length of which is at least or at least about less than, is or is about less than, or between or about any of the following: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90 or 100 contiguous nucleotides.
[0108] Paragraph 28. A cross-linked nucleic acid molecule as described in paragraph 27, wherein the hybridized portion containing the Ap residue of the probe chain and the nc35C>G point mutation site of the target chain has a complementarity of at least or at least about less than, less than or about less than, or between or between about any of the following: 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or has 100% complementarity, except for the position of the Ap residue.
[0109] Paragraph 29. A cross-linked nucleic acid molecule as described in paragraph 24, wherein the probe strand comprises, consists essentially of, or consists of: SEQ ID NO:3 or a fragment thereof comprising 5'GCXGG; SEQ ID NO:4 or a fragment thereof comprising 5'GAXGG; SEQ ID NO:5 or a fragment thereof comprising 5'GCXTG; SEQ ID NO:6 or a fragment thereof comprising 5'GCXCG; SEQ ID NO:7 or a fragment thereof comprising 5'GCXAG; SEQ ID NO:8 or a fragment thereof comprising 5'GCXGC; SEQ ID NO:9 or a fragment thereof comprising 5'GCXCG; SEQ ID NO:10 or a fragment thereof comprising 5'GCXAC; SEQ ID NO:11 or a fragment thereof comprising 5'GCXTGG; SEQ ID NO:12 or a fragment thereof comprising 5'GCXCGG; SEQ ID NO:13 or a fragment thereof comprising 5'GCXGGG; or SEQ ID NO: 14 or a fragment thereof comprising 5'GCXAGG, wherein X is said Ap residue; optionally, wherein said probe strand comprises, consists essentially of, or consists of the sequence TTGGAGCTGCXAGGCGTAGGCA (SEQ ID NO: 14) or a fragment thereof comprising 5'GCXAGG.
[0110] Paragraph 30. A cross-linked nucleic acid molecule as described in any of paragraphs 24 to 29, wherein the probe strand and / or the target strand comprises a terminal extension covalently attached to the 5' end, the 3' end, or both the 5' end and the 3' end of the probe; optionally, wherein the terminal extension is covalently attached to the 3' end of the strand and is selected from the group consisting of: poly(dC) (3-33), poly(dG) (3-33), poly(dA) (3-33), poly(dT) (3-33) and poly(dN) (3-33), wherein N is any combination of 2'-deoxycytidine, 2'-deoxyguanosine, 2'-deoxyadenosine, thymine, abasic, inosine, xanthosine, 7-methylguanosine, dihydrouridine or 5-methylcytidine.
[0111] Example
[0112] The breadth and scope of the present disclosure should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
[0113] Materials and methods.
[0114] DNA oligonucleotides were purchased from Integrated DNA Technologies (IDT, Coralville, IA). 32[P]-ATP was purchased from Perkin Elmer Life Science, uracil DNA glycosylase was purchased from New England Biolabs (Ipswitch, MA), piperidine and acrylamide were purchased from Fisher Scientific (Waltham, MA), and sodium cyanoborohydride and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
[0115] Cross-linking reaction.
[0116] DNA duplexes were prepared by mixing in MOPS (50 mM, pH 7) containing NaCl (100 mM). 32 P-labeled 2'-deoxyuracil-containing oligonucleotides were mixed with a slight excess of complementary strands, the mixture was heated to 90°C, and then cooled to room temperature (24°C). Ap sites were generated by treatment with uracil DNA glycosylase (UDG, 10 units / ml final concentration) for 40 minutes at 37°C in a solution consisting of Tris-HCl (20 mM, pH 8 at 25°C), dithiothreitol (1 mM), EDTA (1 mM), MOPS (25 mM, pH 7), and NaCl (10 mM). The DNA was precipitated with ethanol, and the duplex was redissolved in a solution consisting of sodium acetate (750 mM, pH 5.2) buffer containing NaCNBH3 (200 mM). After incubation at 37°C for 24 hours, the DNA was precipitated with ethanol, redissolved in formamide loading buffer, and the products were analyzed by electrophoresis on a denaturing 20% polyacrylamide gel. After separation, the gel was washed with water and the samples were washed with water. 32 P-labeled oligonucleotides were visualized by phosphochromatography analysis.
[0117] To verify that UDG treatment successfully generated an Ap site in the strand, the oligonucleotides were heated in an aqueous piperidine solution (100 mM) at 90°C for 30 min to induce strand cleavage at the Ap site. The resulting DNA was dried in a Speed-Vac concentrator, redissolved in formamide loading buffer, and analyzed by gel electrophoresis. In time course experiments, aliquots of the reaction mixture were removed at selected time points and frozen in dry ice prior to gel electrophoresis analysis. In experiments involving mixtures of WT and mutant KRAS sequences, 32P-labeled AP-containing probe strands were added to mixtures containing different ratios of WT and mutant KRAS sequences and processed as described above. Footprint experiments to correctly find the cross-link attachment positions on the target strand were performed as previously described (Johnson, 2013; Luce, 2001). Error bars reflect the standard deviation of the mean. Typical cross-linking reactions were performed in triplicate using a single batch of labeled probes. The cross-linking reactions in duplexes W and X were performed in triplicate using at least four different batches of labeled probes (i.e., at least twelve separate cross-linking reactions). The slightly larger standard deviations observed for duplexes W and X are due to the fact that the cross-linking yield variation between batches of labeled probes is slightly greater than the cross-linking yield variation observed in three replicates using a single batch of labeled probes. This may reflect batch-to-batch variation in salt impurities or specific activity associated with the labeled AP-containing probe strands.
[0118] Human KRAS gene SEQ ID NO: 15
[0119] Sequence Listing <110> THE CURATORS OF THE UNIVERSITY OF MISSOURI GATES, Kent Gu Liqun (GU, Li-Qun) NEJAD, Maryam I GUO, Xu <120> Selective covalent capture of DNA sequences <130> P22JM1WN00096US <150> 62 / 884,867 <151> 2019-08-09 <160> 15 <170> PatentIn version 3.5 <210> 1 <211> twenty one <212> DNA <213> Homo sapiens <400> 1 tgcctacgcc agcagctcca a 21 <210> 2 <211> twenty one <212> DNA <213> Homo sapiens <400> 2 tgcctacgcc accagctcca a 21 <210> 3 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 1 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 3 ttggagctgc nggcgtaggc a 21 <210> 4 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 2 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 4 ttggagctga nggcgtaggc a 21 <210> 5 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 3 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 5 ttggagctgc ntgcgtaggc a 21 <210> 6 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 4 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 6 ttggagctgc ncgcgtaggc a 21 <210> 7 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 5 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 7 ttggagctgc nagcgtaggc a 21 <210> 8 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 6 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 8 ttggagctgc ngcgtaggca 20 <210> 9 <211> 19 <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 7 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 9 ttggagctgc ncgtaggca 19 <210> 10 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 8 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 10 ttggagctgc nacgtaggca 20 <210> 11 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 9 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 11 ttggagctgc ntggcgtagg ca 22 <210> 12 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 10 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 12 ttggagctgc ncggcgtagg ca 22 <210> 13 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 11 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 13 ttggagctgc ngggcgtagg ca 22 <210> 14 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic probe 12 <220> <221> misc_feature <223> n is an abasic nucleic acid residue (Ap) <220> <221> misc_feature <222> (11)..(11) <223> n is a, c, g, or t <400> 14 ttggagctgc naggcgtagg ca 22 <210> 15 <211> 567 <212> DNA <213> Homo sapiens <400> 15 atgactgaat ataaacttgt ggtagttgga gctggtggcg taggcaagag tgccttgacg 60 atacagctaa ttcagaatca ttttgtggac gaatatgatc caacaataga ggattcctac 120 aggaagcaag tagtaattga tggagaaacc tgtctcttgg atattctcga cacagcaggt 180 caagaggagt acagtgcaat gagggaccag tacatgagga ctggggaggg ctttctttgt 240 300 aaaagagtta aggactctga agatgtacct atggtcctag taggaaataa atgtgatttg 360 ccttctagaa cagtagacac aaaacaggct caggacttag caagaagtta tggaattcct 420 tttattgaaa catcagcaaa gaagacag ggtgttgatg atgccttcta tacattagtt 480 cgagaaattc gaaaacataa agaaaagatg agcaaagatg gtaaaagaa gaaaagaag 540 567
Claims
1. A method for producing covalently cross-linked nucleic acid strands, the method comprising incubating a hybridized double-stranded nucleic acid molecule, the hybridized double-stranded nucleic acid molecule comprising: (i) a target strand comprising 2'-deoxyguanosine (dG) to be cross-linked (target dG); and (ii) an at least partially complementary probe strand comprising an abasic (Ap) residue, wherein in the hybridized nucleic acid molecule, the Ap residue of the probe strand is located immediately 3' to the nucleotide residue in the probe strand that is directly opposite to the target dG in the target strand, and wherein incubating occurs under conditions that allow for formation of covalent cross-links between said Ap residues of said probe strand and said target dG; Furthermore, in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue 5' and 3' to include the Ap residue comprises: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, (ii) a mismatch between the nucleotide residue immediately 3' to the Ap residue of the probe strand and the directly opposite residue on the target strand; (iii) a sequence that forms a bulge in the target strand; and / or (iv) a sequence that forms a bulge in the probe strand; This results in covalently cross-linked nucleic acid chains.
2. The method of claim 1, wherein in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue at the 5' and 3' positions including the Ap residue comprises: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, wherein the nucleotide residue immediately 5' to the Ap residue on the probe strand is A, T or G; (ii) a sequence that forms a bulge in the probe strand; wherein the probe strand sequence forming a bulge in the probe strand comprises an insertion of a nucleotide having no corresponding residue in the target strand sequence immediately 3′ to the Ap residue in the probe strand, wherein the insertion is an A insertion.
3. The method of claim 1, wherein the incubation is in NaCNBH 3 occurs in the presence of; and / or Wherein said incubation occurs at a pH of 4.5-6.
0.
4. The method according to claim 1, in: (i) the target strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 5' to the target dG residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40, or 50 nucleotides 3' to the target dG residue; and / or (ii) the probe strand comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 5' to the Ap residue and at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 40 or 50 nucleotides 3' to the Ap residue.
5. The method according to claim 4, in: (i) the target strand is at least , is , or is between any of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides in length; (ii) the length of the probe strand is less than, is, or is between any of: 100, 90, 80, 70, 60, 50, 40, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, or 12 nucleotides; and / or (iii) the hybridized nucleic acid molecule comprises a hybridized sequence portion containing the Ap residue of the probe strand and the target dG residue of the target strand, the length of which is at least 100, 150, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 6. The method of claim 5, wherein the hybridized portion containing the Ap residue of the probe strand and the target dG residue position of the target strand, excluding the position of the Ap residue, has a complementarity of at least, or between any of: 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or has 100% complementarity.
7. The method of claim 1, wherein the presence of the target dG residue in the target strand is to be detected and / or identified.
8. The method according to claim 1, A hybrid double-stranded molecule comprising a cross-link between the Ap residue of the probe strand and the target dG residue of the target strand is distinguishable in stability and / or gel mobility from an identical hybrid double-stranded molecule that is also cross-linked except for having a dC substitution at the target dG position of the target strand.
9. The method of claim 1, further comprising detecting covalent cross-linking of the probe strand to the target strand; The detection is performed by gel electrophoresis, thermal stability monitoring, fluorescence, electrochemistry, surface plasmon resonance or nanopore-based sensors.
10. A method for detecting the presence or absence of a dG residue (target dG) at a specific position in a target nucleic acid strand, the method comprising incubating a hybridized double-stranded nucleic acid molecule, the hybridized double-stranded nucleic acid molecule comprising: (i) target strand; and (ii) an at least partially complementary probe strand comprising an abasic (Ap) residue, wherein the Ap residue of the probe strand is located at a position immediately 3' to a nucleotide residue in the probe strand that is directly opposite to a specific position in the target strand to detect the presence or absence of the target dG residue, wherein said incubation occurs under conditions that allow for the formation of covalent cross-links between said Ap residues in said probe strand and said target dG residues, when present, in said target strand; Furthermore, in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue 5' and 3' to include the Ap residue comprises: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, (ii) a mismatch between the nucleotide residue immediately 3' to the Ap residue of the probe strand and the directly opposite residue on the target strand; (iii) a sequence that forms a bulge in the target strand; and / or (iv) a sequence that forms a bulge in the probe strand; and detecting whether the target strand and the probe strand are cross-linked; The method described herein does not involve diagnosis of a disease.
11. The method of claim 10, wherein in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue 5' and 3' to include the Ap residue comprises: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, wherein the nucleotide residue immediately 5' to the Ap residue on the probe strand is A, T or G; or (iv) a sequence forming a bulge in the probe strand; wherein the probe strand sequence forming a bulge in the probe strand comprises an insertion of a nucleotide having no corresponding residue in the target strand sequence immediately 3′ to the Ap residue in the probe strand, and wherein the insertion is an insertion of A.
12. The method of claim 11, wherein target dG is present at a specific position in the target strand and a covalent cross-link is formed between the Ap residue in the probe strand and the target dG in the target strand, and wherein the method detects the presence of the dG residue in the target strand, or wherein target dG is absent at a specific position in the target strand and no covalent cross-links are formed between the Ap residue in the probe strand and the target dG, and wherein the method detects the absence of a dG residue in the target strand.
13. The method of claim 10 or 11, wherein the incubation is in NaCNBH 3 occurs in the presence of; and / or Wherein the incubation occurs at a pH of 4.5-6.
0.
14. A method for detecting a mutation in a wild-type sequence, the method comprising detecting the presence or absence of a target dG residue at a specific position in a target chain according to any one of claims 10 to 13; wherein the method does not involve diagnosis of a disease.
15. The method of claim 14, wherein the target dG residue is present at a specific position in the target chain and the mutation comprises a T→G, A→G, or C→G mutation; or wherein the dG residue is not present at a specific position in the target chain and the mutation comprises a G→T, G→A, or G→C mutation.
16. A method for detecting the presence of dG residues in a nucleic acid strand, the method comprising incubating a hybridized double-stranded nucleic acid molecule, the hybridized double-stranded nucleic acid molecule comprising: (i) a target strand comprising a dG residue to be detected (target dG); and (ii) an at least partially complementary probe strand comprising an abasic (Ap) residue, wherein in the hybridized molecule, the Ap residue of the probe strand is located immediately 3' to the nucleotide residue in the probe strand that is directly opposite to the target dG residue in the target strand, and wherein incubating occurs under conditions that allow for the formation of covalent cross-links between said Ap residues in said probe strand and said target dG residues in said target strand, and detecting a covalent cross-link between the Ap residue in the probe strand and the target strand, and, in the hybridized nucleic acid molecule, a segment of the probe strand immediately flanking the Ap residue at 5′ and 3′ including the Ap residue comprises: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, (ii) a mismatch between the nucleotide residue immediately 3' to the Ap residue of the probe strand and the directly opposite residue on the target strand; (iii) a sequence that forms a bulge in the target strand; and / or (iv) a sequence that forms a bulge in the probe strand; thereby detecting the presence of the target dG residue in the target chain; The method described herein does not involve diagnosis of a disease.
17. The method of claim 16, wherein in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue at the 5' and 3' positions including the Ap residue comprises or consists of composition: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, wherein the nucleotide residue immediately 5' to the Ap residue on the probe strand is A, T or G; or (iv) a sequence forming a bulge in the probe strand; wherein the probe strand sequence forming a bulge in the probe strand comprises an insertion of a nucleotide having no corresponding residue in the target strand sequence immediately 3′ to the Ap residue in the probe strand, wherein the insertion is an insertion of A.
18. The method of claim 16 or 17, wherein the incubation is in NaCNBH 3 occurs in the presence of; and / or Wherein said incubation occurs at a pH of 4.5-6.
0.
19. The method of claim 16 or 17, wherein the covalent cross-linking of the probe strand and the target strand is detected by gel electrophoresis, thermal stability monitoring, fluorescence, electrochemistry, surface plasmon resonance, or a nanopore-based sensor, and optionally wherein the covalent cross-linking of the probe strand and the target strand is detected by a nanopore-based sensor.
20. The method of claim 1, 10, or 16, wherein the probe strand and / or the target strand comprises a terminal extension covalently attached to the 5' end, the 3' end, or both the 5' end and the 3' end of the strand.
21. The method of claim 20, wherein the terminal extension is covalently attached to the 3' end of the strand and is selected from the group consisting of: poly(dC) (3-33) , poly(dG) (3-33) ,poly(dA) (3-33) , poly (dT) (3-33) and poly(dN) (3-33) , wherein N is any combination of 2'-deoxycytosine, 2'-deoxyguanosine, 2'-deoxyadenosine, thymine, abasic, inosine, xanthosine, 7-methylguanosine, dihydrouridine, or 5-methylcytidine.
22. A covalently cross-linked hybridized double-stranded nucleic acid molecule, the covalently cross-linked hybridized double-stranded nucleic acid molecule comprising a probe strand comprising an abasic (Ap) residue and a target strand comprising a 2'-deoxyadenosine (dG) residue, wherein the Ap residue is located at a position immediately 3' to a nucleotide residue in the probe strand that is directly opposite to the dG residue in the target strand, and wherein the Ap residue is covalently cross-linked to the dG residue in the target strand that is directly opposite to a nucleotide residue in the probe strand that is immediately 3' to the AP residue; Furthermore, in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue 5' and 3' to include the Ap residue comprises: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the target dG, (ii) a mismatch between the nucleotide residue immediately 3' to the Ap residue of the probe strand and the directly opposite residue on the target strand; (iii) a sequence that forms a bulge in the target strand; and / or (iv) a sequence forming a bulge in the probe chain.
23. The covalently cross-linked hybridized double-stranded nucleic acid molecule of claim 18, wherein in the hybridized nucleic acid molecule, the segment of the probe strand immediately flanking the Ap residue at the 5' and 3' positions including the Ap residue comprises or consists of composition: (i) a mismatch between the nucleotide residue immediately 5' to the Ap residue on the probe strand and the dG residue to be cross-linked (target dG), wherein the nucleotide residue immediately 5' to the Ap residue on the probe strand is A, T or G; (iv) a sequence forming a bulge in the probe strand; wherein the sequence forming a bulge in the probe strand comprises an insertion of a nucleotide having no corresponding residue in the target strand sequence immediately 3′ to the Ap residue in the probe strand, and wherein the insertion is an insertion of A.
24. The cross-linked nucleic acid molecule of claim 22 or 23, wherein the probe strand and / or the target strand comprises a terminal extension covalently attached to the 5' end, the 3' end, or both the 5' end and the 3' end of the strand.
25. The cross-linked nucleic acid molecule of claim 24, wherein the terminal extension is covalently attached to the 3' end of the strand and is selected from the group consisting of: poly(dC) (3-33) , poly(dG) (3-33) ,poly(dA) (3-33) , poly (dT) (3-33) and poly(dN) (3-33) , wherein N is any combination of 2'-deoxycytosine, 2'-deoxyguanosine, 2'-deoxyadenosine, thymine, abasic, inosine, xanthosine, 7-methylguanosine, dihydrouridine, or 5-methylcytidine.
